3449 results for «2025»
3449 results
EuroPCR 2025 – One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
21 May 2025
Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among them is the...
Major EuroPCR 2025 LBT - 4D-ACS: one-month DAPT followed by dose reduction of prasugrel after drug-coated stent insertion in acute coronary syndrome
21 May 2025 – From EuroPCR 2025
In this EuroPCR 2025 interview, Davide Capodanno and Woong Chol Kang discuss antithrombotic therapy in patients with acute coronary syndromes, focusing on the design and outcomes of the 4D-ACS trial. They describe the patient population enrolled in the study and introduce the two de-escalation strategies investigated:...
Hotline from EuroPCR 2025 - Five-year outcomes from the Evolut low risk TAVR bicuspid study
21 May 2025 – From EuroPCR 2025
Simon Redwood and John Forrest exchange insights on the Evolut Low Risk Bicuspid Study, which explores transcatheter aortic valve replacement (TAVR) in younger, low-risk patients with bicuspid aortic valves—an anatomy often excluded from earlier trials.
They review the trial design, patient characteristics, and results, comparing outcomes with...
EuroPCR 2025: RESIL-Card achieves a major milestone - The resilience tool is ready for pilot testing!
20 May 2025
Launched in December 2023 by our community through the ‘We CARE Alliance’ and co-funded by the EU4Health work programme, the mission of the RESIL-Card project is to ensure that essential healthcare services for people with cardiovascular (CV) diseases are maintained during crises. Specifically, the project aims to...
SMT’s Supraflex Cruz shows consistent and robust clinical outcomes across key global studies presented at TCT 2025
29 Oct 2025
Jupiter Endovascular announces positive results from SPIRARE I first-in-human study presented at TCT 2025
26 Oct 2025
Meril Life Sciences presents one-year outcomes from the LANDMARK randomized controlled trial at PCR London Valves 2025
16 Nov 2025
Indirect Industry Supported Grants for #PCRLV
Useful links in Interventional Cardiology
12 Oct 2016
We would like to share useful information and links to resources with you on Interventional Cardiology, medical professional societies, specialised websites and scoring tools.
Major LBTs from EuroPCR 2025 - Meta-Analysis of individual patient data from the PROTECTED TAVR and BHF PROTECT-TAVI studies
22 May 2025 – From EuroPCR 2025
Stroke remains one of the most feared complications of TAVI—for both patients and physicians. In this EuroPCR 2025 video interview, Bernard Prendergast and Rajesh Kharbanda examine the role of cerebral protection during TAVI procedures, in light of two randomised trials: PROTECTED TAVR and BHF PROTECT-TAVI. While...
EuroPCR 2025: Late-breaking data demonstrate sustained significantly lower event rates with Elixir Medical’s DynamX® Bioadaptor over drug-eluting stent through three Years
21 May 2025
Shockwave Medical study confirms benefit of IVL-first strategy in real-world female patients with complex calcified lesions in late-breaking data presentation at EuroPCR 2025
20 May 2025
Tendyne transcatheter mitral valve system in patients with severe mitral annular calcification: one-year outcomes from the SUMMIT Severe MAC cohort
27 Oct 2025
Luigi Biasco interviews Paul Sorajja about the SUMMIT MAC Pivotal Trial he presented at TCT 2025, in San Francisco.
Author
Author
Sirolimus-eluting iron bioresorbable scaffold in coronary artery disease: two-year results of IRONMAN-II randomised controlled trial
25 Oct 2025
Alex Sticchi interviews Lei Song on the IRONMAN II trial he presented at TCT 2025, in San Francisco.
Author
Author
Surgical left atrial appendage occlusion in VHD without AF: OPINION Trial
03 Sep 2025
Alex Sticchi provides his take on the results of the OPINION trial presented by Yang Wang at the ESC Congress 2025 in Madrid.
Author
Randomised comparison of intravascular lithotripsy vs. cutting balloon treatment in calcified coronary artery disease – The Short-CUT trial
27 Oct 2025
Aaysha Cader provides her take on the Short-CUT trial presented by Suzanne J. Baron at TCT 2025, in San Francisco.
Author
The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation
01 Sep 2025
Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.
Author
![The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]](https://www.pcronline.com/var/pcrov3/storage/images/pcronline/news/congress-coverages/esc/2025/aquatic-trial-quitting-versus-using-aspirin-therapy-patients-stabilized-cad-stenting-long-term-oral-anticoagulation/27448089-9-eng-GB/The-AQUATIC-trial-Assessment-of-quitting-versus-using-aspirin-therapy-in-patients-with-stabilized-coronary-artery-disease-after-stenting-who-requi_image_responsive_6.jpg)
Comparison of drug-coated versus conventional balloons for treatment of side branches of bifurcation lesions: the OCVC-BIF study
29 Oct 2025
Ali Nazmi Calik provides his take on the OCVC-BIF study presented by Takayuki Ishihara at TCT 2025, in San Francisco.
Author
TACSI: Dual or single antiplatelet therapy after CABG in patients with acute coronary syndrome
03 Sep 2025
Aaysha Cader provides her take on TACSI presented by Anders Jeppsson at ESC Congress 2025 in Madrid.
Author
A randomised, multicenter, non-inferiority comparison of intravascular lithotripsy and super-high-pressure non-compliant balloons for treatment of calcified and refractory coronary lesions - The VICTORY trial
27 Oct 2025
Mirvat Alasnag provides her take on the VICTORY trial presented by Matthias Bossard at TCT 2025 in San Francisco.
Author
